CARotid plaqUe StabilizatiOn and regression with evolocumab: the CARUSO Study

The CARUSO study, a randomized trial of patients with significant carotid stenosis, found that while adding evolocumab to standard lipid-lowering therapy did not statistically significantly improve plaque stabilization or regression compared to therapy alone, it was associated with a sevenfold reduction in major adverse vascular events and prevented morphological deterioration, suggesting evolocumab should be considered standard treatment for this population.

The Gist

🚗 The Big Picture: Fixing the "Rust" in Your Pipes

Imagine your arteries are like garden hoses that carry water (blood) to your brain. Over time, these hoses can get clogged with "rust" and gunk. This gunk is called plaque.

If the gunk gets too thick, it narrows the hose (stenosis). If the gunk is soft and unstable, it's like a rusty pipe that might burst or send a chunk of rust flying downstream, blocking the water flow and causing a stroke.

The goal of this study was to see if adding a special "super-cleaning" drug (Evolocumab) to the standard cleaning routine could not only stop the rust from getting worse but actually clean the hose back up and make the rust harder and safer.

---

🧪 The Experiment: Two Cleaning Crews

The researchers took 170 people who had significant gunk in their neck arteries (carotid arteries) and high levels of "bad cholesterol" (LDL). They split them into two teams:

1. Team Standard (LLT): These patients got the best standard cleaning kit available: a strong statin drug (Rosuvastatin) plus a helper drug (Ezetimibe). Think of this as a high-quality detergent.
2. Team Super-Clean (ELLT): These patients got the exact same standard kit, PLUS a monthly injection of a powerful new drug called Evolocumab. Think of this as the high-quality detergent plus a heavy-duty industrial solvent.

The Question: Does adding the "industrial solvent" actually clean the pipes better than the detergent alone?

---

🔍 What They Looked For

The doctors used a special ultrasound camera (like a sonar for the inside of the hose) to take pictures of the gunk at the start, after 6 months, and after 12 months. They were looking for two things:

1. Stabilization (Making the Rust Hard): Did the soft, dangerous gunk turn into hard, safe, rocky gunk? (Like turning wet mud into dry concrete).
2. Regression (Shrinking the Gunk): Did the gunk actually get smaller, making the pipe wider again?

---

📊 The Results: The Numbers Game

Here is what happened after one year:

• The "Super-Clean" Team (Evolocumab):

  • They did a little better at turning soft gunk into hard, safe gunk.
  • They did a little better at shrinking the gunk.
  • However: When they ran the math, these improvements were not statistically significant. It was like Team Super-Clean cleaned the hose 5% better than Team Standard, but the difference wasn't big enough to say, "Yes, the solvent definitely worked better than the detergent" with 100% certainty.

• The "Standard" Team (Statin Only):

  • They also improved, but not as much as the other team.
  • The Big Problem: In this group, the gunk actually got worse in some cases. The "soft" dangerous gunk turned into more dangerous types in several patients.

• The Cholesterol Drop:

  • Team Super-Clean dropped their "bad cholesterol" levels by 73%.
  • Team Standard dropped theirs by 48%.
  • Team Super-Clean was clearly the winner at lowering the numbers.

---

🚨 The Real Winner: Safety and Survival

Here is the most important part of the story. While the "cleaning" results were a bit mixed, the safety results were a landslide victory.

• Team Standard (Statin Only): 14.6% of these patients had a major bad event (like a heart attack, stroke, or needing surgery).
• Team Super-Clean (Evolocumab): Only 2.4% had a major bad event.

The Analogy:
Imagine two groups of people driving on a foggy road.

• Group A (Standard) had a few more accidents.
• Group B (Super-Clean) had almost no accidents.

Even though the "Super-Clean" group didn't prove they cleaned the car engine perfectly better in the lab, they proved that their drivers stayed alive and safe much more often.

The study found that not taking the extra drug (Evolocumab) was the only reason people had accidents. If you took the extra drug, your risk of a major vascular event dropped by seven times.

---

💡 The Takeaway: What Should You Do?

The researchers concluded that for people with clogged neck arteries and high cholesterol:

1. Don't wait for the "perfect" cleaning: Even if the plaque doesn't shrink visibly on the ultrasound, the drug makes the plaque safer and stops it from causing heart attacks or strokes.
2. The "Super-Clean" approach is the new standard: They suggest that everyone with these specific artery problems should probably get the extra drug (Evolocumab) on top of their regular statins.
3. It's about the whole system: The drug didn't just clean the neck; it seemed to protect the whole body's plumbing system.

In short: Adding Evolocumab is like upgrading from a regular raincoat to a high-tech, waterproof suit. You might not see a huge difference in how dry your shirt feels immediately, but when the storm hits, the high-tech suit keeps you from getting soaked (or worse).

Note: This study is a "preprint," meaning it's new research that hasn't been fully checked by other scientists yet, but the results are very promising and suggest a major shift in how we treat artery disease.

Technical Summary

1. Problem Statement

While Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors like evolocumab have been proven to promote coronary plaque regression and reduce cardiovascular events in patients with coronary artery disease (CAD), their specific impact on carotid artery plaques (CP) remains under-investigated. Current guidelines recommend aggressive lipid-lowering therapy (LLT) for patients with carotid stenosis, yet many patients remain undertreated or fail to reach LDL-C targets due to statin intolerance or insufficient efficacy. The study addresses the gap in knowledge regarding whether adding evolocumab to optimized LLT can induce morphological stabilization (MS) and plaque regression (PR) in carotid arteries, and whether this translates to a reduction in major adverse vascular events (MAVE).

2. Methodology

• Study Design: Single-center, investigator-initiated, randomized controlled trial.
• Population: 170 asymptomatic patients with internal carotid stenosis $\ge$50% and LDL-C $\ge$100 mg/dL.
  • Exclusion: Age <18 or >80, prior stroke/TIA within 12 months, complete carotid occlusion, or known PCSK9-inhibitor intolerance.
• Intervention Groups:
  1. ELLT (Evolocumab on top of LLT): Optimized LLT (Rosuvastatin 20 mg + Ezetimibe 10 mg) + Evolocumab 140 mg subcutaneously every 2 weeks.
  2. LLT (Control): Optimized LLT (Rosuvastatin 20 mg + Ezetimibe 10 mg) alone.
  • Note: All patients were uptitrated to the optimized LLT regimen at enrollment to ensure a uniform background therapy.
• Endpoints:
  • Primary: A composite of Morphological Stabilization (MS) at 6 months (shift from high-risk types I-II to low-risk types III-IV) and/or Plaque Regression (PR) at 12 months (reduction in stenosis degree by $\ge$5%).
  • Secondary: LDL-C reduction at 12 months, morphological deterioration (MD), and Major Adverse Vascular Events (MAVE: cardiac death, stroke, MI, revascularization).
• Imaging: Serial Duplex Ultrasound (DUS) performed by blinded vascular surgeons at baseline, 6 months, and 12 months. Plaque morphology was classified into four types (I-IV) based on echogenicity.
• Statistical Analysis: Intention-to-treat analysis using T-tests, Chi-square, and logistic regression/Cox proportional-hazards models for predictors.

3. Key Contributions

• Largest RCT to Date: This is the largest randomized trial specifically evaluating the impact of evolocumab on carotid plaque morphology and regression.
• Dynamic Nature of Plaques: The study highlights that carotid plaque morphology is a dynamic event; even "low-risk" plaques can deteriorate into high-risk types without aggressive lipid lowering.
• Therapeutic Uptitration Protocol: Unlike previous studies that compared evolocumab against variable baseline therapies, CARUSO standardized the background therapy (Rosuvastatin + Ezetimibe) for all participants, providing a rigorous test of the add-on effect of evolocumab.
• Clinical Outcome Correlation: It links morphological changes (or lack thereof) directly to hard clinical endpoints (MAVE) in a carotid-specific cohort.

4. Results

• Demographics: 165 patients (175 plaques) were analyzed. Mean age was 72 years; 61% male; 40% had diabetes. Baseline mean stenosis was 57%.
• Lipid Profile:
  • LDL-C Reduction: At 12 months, the ELLT group achieved a -73.5% reduction in LDL-C (mean 34 mg/dL), compared to -48.3% in the LLT group (mean 64 mg/dL). The difference was statistically significant ($p=0.0001$).
  • Target Achievement: 83.4% of ELLT patients reached LDL-C <55 mg/dL vs. 43.1% in the LLT group.
• Plaque Morphology (Primary Endpoint):
  • Morphological Stabilization (MS): Occurred in 10.3% of the ELLT group vs. 0% in the LLT group at 6 months (not statistically significant, $p=0.29$).
  • Plaque Regression (PR): Occurred in 43% of ELLT vs. 35.1% of LLT at 12 months (not statistically significant, $p=0.42$).
  • Composite Primary Endpoint: Met in 44.3% (ELLT) vs. 35.1% (LLT), $p=0.26$.
  • Morphological Deterioration (MD): Significantly higher in the LLT group. The shift from low-risk to high-risk types was significantly more frequent in the LLT group at both 6 and 12 months ($p=0.03$).
• Clinical Events (MAVE):
  • Incidence: MAVE occurred in 2.4% of the ELLT group (2 patients) vs. 14.6% of the LLT group (12 patients).
  • Significance: This difference was statistically significant ($p=0.005$).
  • Predictors: Multivariate analysis identified the absence of evolocumab as the only independent predictor of MAVE (Odds Ratio 7.0, $p=0.014$).
• Safety: No significant adverse events related to evolocumab were reported. Statin discontinuation due to side effects occurred in both groups.

5. Significance and Clinical Implications

• Prevention of Deterioration: While the study did not reach statistical significance for the primary composite endpoint of stabilization/regression, it demonstrated that evolocumab significantly prevents the deterioration of carotid plaques from low-risk to high-risk morphological types, a phenomenon observed frequently in the LLT-only group.
• Clinical Event Reduction: The most striking finding is the sevenfold reduction in MAVE in the evolocumab group. This suggests that the systemic anti-atherosclerotic effects of evolocumab (beyond just carotid plaque morphology) provide profound clinical protection.
• Treatment Paradigm: The authors conclude that for patients with carotid stenosis $\ge$50% and LDL-C not at target, Evolocumab on top of optimized LLT should be considered standard treatment, regardless of the initial plaque morphology.
• Limitations: The study was limited by a relatively small sample size (leading to lack of statistical power for the primary imaging endpoint) and the use of DUS rather than MRI (which is more sensitive for plaque composition). However, the robust clinical outcome data supports the efficacy of the therapy.

Conclusion: The CARUSO study provides compelling evidence that adding evolocumab to optimized statin/ezetimibe therapy not only achieves superior LDL-C lowering but also stabilizes carotid plaque morphology and drastically reduces the risk of major vascular events in patients with significant carotid stenosis.